Exhibit 99.1

NPS Pharma Reports First-Quarter 2014 Financial Results

Net global Gattex®/Revestive® sales of $18 million representing 17 percent sequential growth

Full-year net sales guidance revised to $100 to $110 million from $110 to $120 million to reflect impact of delays in January and February sales

Natpara® BLA review continues to progress with PDUFA date of October 24, 2014

Conference call today at 8:30 AM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)--May 8, 2014--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported its results for the quarter ended March 31, 2014.

NPS Pharma reported net global product sales of $17.9 million for the first quarter of 2014, compared to $0.7 million for the same period last year, representing 17% sequential growth over net sales in the fourth quarter of 2013. The company experienced a slower-than-expected start in adding new Gattex® (teduglutide [rDNA origin]) patients and refills in the U.S. NPS Pharma now expects to achieve full-year 2014 net sales guidance of $100 to $110 million, representing more than 200 percent year-over-year growth in the company’s Short Bowel Syndrome (SBS) franchise.

“We are pleased to report that physician and patient interest in Gattex continues to be very high,” said Francois Nader, MD, president and chief executive officer of NPS Pharma. “After a challenging January and February, which were partially affected by severe winter weather, we saw key metrics bounce back for prescriptions in March and April with weekly averages exceeding those in the fourth quarter. In addition, we noted significant improvements in the time-to-dispense and fill-rate of new prescriptions in 2014. As we continue to learn more about the SBS market dynamics, we are readily adapting our commercial strategy and operations to ensure we fully capture the significant opportunity that Gattex represents, including increasing the size of our sales organization.”

Dr. Nader added: “We are interacting with the FDA as they actively review our Natpara Biologics License Application and preparing for an FDA Advisory Committee meeting, which has been tentatively scheduled for July 24. We are also happy to report that our regional and key country leadership is in place to support the expansion of NPS Pharma in key international markets. Lastly, we are focused on expanding our pipeline through our clinical program for pediatric Short Bowel Syndrome and the recent filing of an Investigational New Drug Application for NPSP795, which is on track to begin a Phase 2a study in mid-2014.”


The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Thursday, May 8, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Nps Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nps Pharmaceuticals Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account